Does Keytruda Have Allergies Listed as Contraindications?
Keytruda (pembrolizumab) has no absolute contraindications for hypersensitivity or allergies in its FDA-approved labeling. The prescribing information states it should not be used in patients with severe hypersensitivity to pembrolizumab or any of its excipients, such as L-histidine, sucrose, polysorbate 80, or water for injection.[1] Mild allergies do not bar use, but severe reactions (e.g., anaphylaxis) from prior exposure require avoidance.
What Counts as a Severe Hypersensitivity Reaction?
Severe reactions include anaphylaxis, angioedema, or other immediate hypersensitivity during or after infusion. Symptoms like difficulty breathing, swelling, rash, or low blood pressure signal this. The label advises permanent discontinuation after grade 4 hypersensitivity or recurrent grade 3 events.[1] No specific allergens (e.g., foods, pollen) are flagged beyond drug components—reactions stem from immune response to the monoclonal antibody itself.
How Common Are Allergic Reactions to Keytruda?
Infusion reactions occur in 2-5% of patients across trials, mostly mild (chills, fever, itching). Severe cases are rare (<1%), with no difference by underlying cancer type. Pre-medication like antihistamines or steroids isn't routinely required but may be used for prior reactors.[1][2]
Testing or Monitoring for Allergies Before Starting?
No routine allergy testing is recommended. Risk assessment relies on patient history of severe reactions to IV drugs or biologics. Infusions start slow (over 30 minutes) with monitoring for the first cycle. Skin testing for pembrolizumab isn't validated.[1]
What If You've Had Reactions to Similar Drugs?
Cross-reactivity with other PD-1/PD-L1 inhibitors (e.g., Opdivo, Tecentriq) is possible due to similar structures, but not guaranteed—case reports show some patients tolerate switches.[3] Excipients like polysorbate 80 appear in many biologics; allergy to it may prompt caution, though true isolated allergies are uncommon.
[1]: Keytruda Prescribing Information (FDA)
[2]: Keytruda Clinical Pharmacology Review (FDA)
[3]: Journal of Clinical Oncology: Hypersensitivity to PD-1 Inhibitors (2021)